Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells

被引:115
作者
Barilla-LaBarca, ML
Liszewski, MK
Lambris, JD
Hourcade, D
Atkinson, JP
机构
[1] Washington Univ, Sch Med, Div Rheumatol, Dept Med, St Louis, MO 63110 USA
[2] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
D O I
10.4049/jimmunol.168.12.6298
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
C4b and C3b deposited on host cells undergo limited proteolytic cleavage by regulatory proteins. Membrane cofactor protein (MCP; CD46), factor H, and C4b binding protein mediate this reaction, known as cofactor activity, that also requires the plasma serine protease factor I. To explore the roles of the fluid phase regulators vs those expressed on host cells, a model system was used examining complement fragments deposited on cells transfected with human MCP as assessed by FACS and Western blotting. Following incubation with Ab and complement on MCP+ cells, C4b was progressively cleaved over the first hour to C4d and C4c. There was no detectable cleavage of C4b on MCP- cells, indicating that MCP (and not C4BP in the serum) primarily mediates this cofactor activity. C3b deposition was not blocked on MCP+ cells because classical pathway activation occurred before substantial C4b cleavage. Cleavage, though, of deposited C3b was rapid (<5 min) and iC3b was the dominant fragment on MCP- and MCP+ cells. Studies using a function-blocking mAb further established factor H as the responsible cofactor. If the level of Ab sensitization was reduced 8-fold or if Mg2+-EGTA was used to block the classical pathway, MCP efficiently inhibited C3b deposition mediated by the alternative pathway. Thus, for the classical pathway, MCP is the cofactor for C4b cleavage and factor H for C3b cleavage. However, if the alternative pathway mediates C3b deposition, then MCP's cofactor activity is sufficient to restrict complement activation.
引用
收藏
页码:6298 / 6304
页数:7
相关论文
共 45 条
[1]   Apoptosis in systemic lupus erythematosus - Clinical implications [J].
Andrade, F ;
Casciola-Rosen, L ;
Rosen, A .
RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2000, 26 (02) :215-+
[2]   A HUMAN CELL-SURFACE ANTIGEN DEFINED BY A MONOCLONAL-ANTIBODY AND CONTROLLED BY A GENE ON HUMAN CHROMOSOME-1 [J].
ANDREWS, PW ;
KNOWLES, BB ;
PARKAR, M ;
PYM, B ;
STANLEY, K ;
GOODFELLOW, PN .
ANNALS OF HUMAN GENETICS, 1985, 49 (JAN) :31-39
[3]   FORMATION OF COVALENTLY LINKED C3-C3 DIMERS ON IGG IMMUNE AGGREGATES [J].
BARRIO, E ;
ANTON, LC ;
MARQUES, G ;
SANCHEZ, A ;
VIVANCO, F .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1991, 21 (02) :343-349
[4]   Structural requirements for the complement regulatory activities of C4BP [J].
Blom, AM ;
Kask, L ;
Dahlbäck, B .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (29) :27136-27144
[5]   A protective role for innate immunity in autoimmune disease [J].
Carroll, MC .
CLINICAL IMMUNOLOGY, 2000, 95 (01) :S30-S38
[6]   IDENTIFICATION OF AN ADDITIONAL CLASS OF C3-BINDING MEMBRANE-PROTEINS OF HUMAN PERIPHERAL-BLOOD LEUKOCYTES AND CELL-LINES [J].
COLE, JL ;
HOUSLEY, GA ;
DYKMAN, TR ;
MACDERMOTT, RP ;
ATKINSON, JP .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (03) :859-863
[7]  
Devaux P, 1999, EUR J IMMUNOL, V29, P815
[8]   CR3: a general purpose adhesion-recognition receptor essential for innate immunity [J].
Ehlers, MRW .
MICROBES AND INFECTION, 2000, 2 (03) :289-294
[9]   IDENTIFICATION OF THE MEMBRANE GLYCOPROTEIN THAT IS THE C3B RECEPTOR OF THE HUMAN-ERYTHROCYTE, POLYMORPHONUCLEAR LEUKOCYTE, LYMPHOCYTE-B, AND MONOCYTE [J].
FEARON, DT .
JOURNAL OF EXPERIMENTAL MEDICINE, 1980, 152 (01) :20-30
[10]  
FISCHER E, 1986, J IMMUNOL, V136, P1373